Table 3 The time interval from enrollment date to index date of each co-morbidity in the study group
From: Risk factors for the occurrence of visual-threatening posterior capsule opacification
Time interval (months) | ||
|---|---|---|
Mean (SD) | Median (Q1, Q3) | |
All Nd:YAG capsulotomy | 32.12 (31.19) | 25 (7, 45) |
Co-morbidities | ||
Corneal disease | 26.32 (27.18) | 20 (5, 37) |
DED | 22.77 (22.65) | 17 (5, 34) |
Glaucoma | 26.71 (27.58) | 19 (5, 38) |
Uveitis | 21.03 (24.87) | 13 (3, 30) |
AMD | 23.31 (22.96) | 16 (4, 36) |
Hypertension | 28.02 (26.24) | 22 (6, 41) |
DM | 27.73 (27.17) | 20 (6, 41) |
Hyperlipidemia | 25.8 (24.71) | 19 (5, 38) |
Congestive heart failure | 26.55 (24.69) | 20 (6, 41) |
Myocardial infarction | 31.62 (30.11) | 21 (6, 44) |
Cerebrovascular disease | 27.47 (26.5) | 20 (6, 39) |
Peripheral vascular disease | 27.97 (27.38) | 20 (6, 41) |
Dementia | 24.3 (27.37) | 14 (3, 35) |
Chronic pulmonary disease | 29.14 (26.74) | 23 (7, 43) |
Rheumatic disease | 28.49 (24.5) | 25 (8, 43) |
Peptic ulcer disease | 28.28 (26.66) | 22 (7, 41) |
Liver disease | 28.71 (26.51) | 23 (7, 42) |
Hemiplegia or paraplegia | 24.53 (25.98) | 16 (5, 37) |
Renal disease | 26.22 (25.26) | 20 (6, 39) |
Malignancy | 25.7 (23.84) | 20 (6, 39) |
Coagulation defects | 34.92 (38.05) | 22 (7, 51.5) |